Skip to main content
Clinical Trials/CTRI/2019/02/017634
CTRI/2019/02/017634
Recruiting
Phase 2

Randomised Controlled Trial Comparing Efficacy of Zonisamide 25 mg given in addition to standard treatment with standard treatment alone in Tremor dominant Parkinsonâ??s Disease- A Pilot study

Sun Pharmaceutical Industries Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: G20- Parkinsons disease
Sponsor
Sun Pharmaceutical Industries Ltd
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • PD diagnosed according to UKPD Brain Bank criteria
  • Patients who meet criteria for tremor dominant PD, as described in methodology below.
  • Men and women of age 18 to 85\.
  • PD patients on stable dose of antiparkinsonian drug for last 3 months.

Exclusion Criteria

  • Patients of Atypical PD (diagnosed as per clinical criteria)
  • Patients of PD on other non\- antiparkinsonian drugs which might affect tremor, such as beta\-agonists, beta\- blockers, anti\-epileptics such as phenytoin, valproate, carbamazepine.
  • History of psychiatric illness
  • Severe cognitive impairment(MMSE \<\=21\)
  • Hepatic or renal disease
  • Pregnancy and breast feeding
  • Known allergy to Zonisamide

Outcomes

Primary Outcomes

Not specified

Similar Trials